Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays

Monteyne, Tinne; Kesel, Pieter De; Devreese, Katrien

doi:10.1016/j.thromres.2020.04.044

Cited by 19 publications

(28 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, Kopatz et al showed a complete normalization of the CAT traces up to DOACs concentration 80 ng/ml; 7 however, DOAC-Stop ® has never been assessed on the TEG before. CAT results from NPP/ WPP suggested hypercoagulability, as previously reported, 7,9 whereas TEG results suggested hypocoagulability. Factor assays results showed a reduction of factors involved in the intrinsic coagulation pathway, suggesting that DOAC-Stop ® might be activating coagulation through the contact activation pathway, with consumption of these factors.…”

Section: The Effect Of Doac-stop ® On Several Oral and Parenteral Anticoagulantssupporting

confidence: 81%

The effect of DOAC‐Stop^® on several oral and parenteral anticoagulants

Riva

Vella

Hickey

et al. 2021

Int J Lab Hematology

View full text Add to dashboard Cite

Section: The Effect Of Doac-stop ® On Several Oral and Parenteral Anticoagulantssupporting

confidence: 81%

The effect of DOAC‐Stop^® on several oral and parenteral anticoagulants

Riva

Vella

Hickey

et al. 2021

Int J Lab Hematology

View full text Add to dashboard Cite

“…This procoagulant effect seems to be related to slight reduction in tissue factor pathway inhibitor (TFPI). 50,51 The elimination of DOAC presence in plasma using filters like the DP-Filter (5-Diagnostics) or the DOAC-Filter (Diagnostica Stago, France) showed promising results. 39,52 However, potential unintended filtration of coagulation proteins seen with other filtering mechanisms (e.g., von Willebrand factor) may occur, but the interference of DOAC-Stop or DOAC-Remove on these other coagulation proteins has also been found (e.g., interference on TFPI), impacting mainly TGA.…”

Section: Interference Of Doac On Coagulation Assaysmentioning

confidence: 99%

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Adcock²,

et al. 2021

View full text Add to dashboard Cite

In 2018, the International Council for Standardization in Hematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alpha. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author’s personal experience/expert opinion and (3) good laboratory practice.

show abstract

“…Because of the increased necessity of testing patients for LA while on DOAC, several publications have emerged that have suggested the use of an insoluble adsorbent material to eliminate DOACs in vitro. 68,[70][71][72] This DOAC-Stop reagent can be added to samples before testing, and it will not affect screening tests like dRVVT in patients not receiving DOACs. Another potential way to overcome and eliminate the interfering effect of DOACs would be to use a simple charcoal product.…”

Section: Evaluating La Results In Anticoagulated Patientsmentioning

confidence: 99%

Laboratory Approaches to Test the Function of Antiphospholipid Antibodies

Szabó

Antal‐Szalmás

Kerényi

et al. 2021

Semin Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder caused by the presence of aPLs (antiphospholipid antibodies, i.e., anti-β2-glycoprotein I and anti-cardiolipin). Everyday practice in terms of laboratory diagnostics of APS includes determination of aPLs and well-known functional assays assessing for lupus anticoagulant (LA), in turn using various tests. According to recent guidelines, the recommended method for LA identification or exclusion is based on the Russell Viper Venom test and a sensitive activated partial thromboplastin time assay. Despite the fact that LA can be quantified in laboratory practice in this way, LA is still used as a binary parameter that is just one of the risk factors of thrombosis in APS. As of today, there are no other functional assays to routinely assess the risk of thrombosis in APS. It is well-known that APS patients display a wide range of clinical outcomes although they may express very similar laboratory findings. One way to solve this dilemma, could be if antibodies could be further delineated using more advanced functional tests. Therefore, we review the diagnostic approaches to test the function of aPLs. We further discuss how thrombin generation assays, and rotational thromboelastometry tests can be influenced by LA, and how experimental methods, such as flow cytometric platelet activation, surface plasmon resonance, or nano differential scanning fluorimetry can bring us closer to the puzzling interaction of aPLs with platelets as well as with their soluble protein ligand. These novel approaches may eventually enable better characterization of aPL, and also provide a better linkage to APS pathophysiology.

show abstract

Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays

Cited by 19 publications

References 11 publications

The effect of DOAC‐Stop^® on several oral and parenteral anticoagulants

The effect of DOAC‐Stop^® on several oral and parenteral anticoagulants

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Laboratory Approaches to Test the Function of Antiphospholipid Antibodies

Contact Info

Product

Resources

About

Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays

Cited by 19 publications

References 11 publications

The effect of DOAC‐Stop® on several oral and parenteral anticoagulants

The effect of DOAC‐Stop® on several oral and parenteral anticoagulants

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Laboratory Approaches to Test the Function of Antiphospholipid Antibodies

Contact Info

Product

Resources

About

The effect of DOAC‐Stop^® on several oral and parenteral anticoagulants

The effect of DOAC‐Stop^® on several oral and parenteral anticoagulants